Uncapping Conflict of Interest?

See allHide authors and affiliations

Science  07 Jun 2013:
Vol. 340, Issue 6137, pp. 1172-1173
DOI: 10.1126/science.1231955

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The U.S. Food and Drug Administration (FDA) calls on advisory committees (ACs) to provide external expert advice and recommendations to "enhance FDA's ability to protect and promote the public health and maintain the public trust" (1). The FDA Safety and Innovation Act (FDASIA) (2) was signed into law in 2012 primarily to reauthorize user-fee programs for drugs, devices, and biosimilars. We discuss concerns about how FDASIA also changes AC financial conflict of interest (COI) requirements.